FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...
Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad ...
The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a ...
Discover innovative immunotherapy strategies that leverage the immune system to combat hematological malignancies effectively ...
News Medical on MSN
New Combination Therapy Shows Promise For Aggressive Lymphoma Resistant To Immunotherapy
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising ...
Enterome has received fast track designation from the US Food and Drug Administration for its lead OncoMimics immunotherapy EO2463, targeting follicular lymphoma in the low tumour burden ...
The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...
At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...
The trial laid the foundation for the Comparative Immunotherapy Program — a program launched a year ago to tap into Penn’s ...
The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results